Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a ...

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Biogen (BIIB – Research Report). The associated price target ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA ...

Biogen reported third-quarter revenue and adjusted earnings that topped expectations. The company also raised its full-year ...

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare ...